18:19 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
18:15 , Feb 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Detection of a panel of circulating tumor cell (CTC)-derived RNA transcripts in blood could help predict survival and disease progression in metastatic melanoma patients receiving immune checkpoint inhibitors. The method scores blood...
19:53 , Oct 12, 2017 |  BC Innovations  |  Translation in Brief

Opening doors for I-O

A...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of VEGF-C could help predict responses to immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A ( MLANA ; MART1) peptide and the...
16:08 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other An...
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Deoxycytidine kinase (DCK)-based in vivo PET imaging of T cell immunotherapies

Imaging TECHNOLOGY: PET T cells engineered to express a PET imaging reporter could help monitor tumor infiltration of chimeric antigen receptor (CAR) and other T cell immunotherapies. Cells expressing a triple mutant of human DCK...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Evolved T-cell receptor (TCR) variants

Drug platforms TECHNOLOGY: Antibody scaffolds Directed evolution of single TCRs could be used to generate variants with novel binding specificities without the need to isolate T cell clones. In vitro, genetically modified variants of a...
08:00 , Feb 7, 2013 |  BC Innovations  |  Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Antigen-specific T cells generated from induced pluripotent stem (iPS) cells derived for adoptive immunotherapy Two separate groups showed that iPS cells derived from mature CD8+...
07:00 , Oct 25, 2012 |  BC Innovations  |  Cover Story

Melanoma's hidden act

Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens. 1 The group...